Schedule 13G ownership disclosure

Stoke Therapeutics Inc

Common Stock · CUSIP: 86150R107

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Morgan Stanley

    Shares: 3,426,739 · Class: 6.5%

  • Morgan Stanley Capital Services LLC

    Shares: 2,879,280 · Class: 5.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000895421-25-000200
Form type
SCHEDULE 13G/A
Filer
MORGAN STANLEY
CIK
CIK 895421
Filed
Feb 03, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub